Thousands Rally at Boston Common Ahead of Massachusetts Cannabis Repeal Vote
Advocates gathered Saturday for the annual Freedom Rally as voters prepare to decide the fate of legal cannabis in November.

A large crowd gathers outdoors holding a 'No Justice No Peace' sign during a protest.
Rally Draws Largest Crowd in Event's History
Organizers estimated more than 8,000 attendees at the 2026 Freedom Rally, marking the event's largest turnout since its founding in 1989. The rally happens annually on the third Saturday in September. This year carried extra weight: Massachusetts voters face Question 4 on the November 5 ballot, a citizen-initiated measure to repeal the state's 2018 adult-use cannabis statute.
Ballot Measure Would Reverse 2016 Legalization
Question 4 seeks to eliminate Chapter 94G of the Massachusetts General Laws, the framework voters approved by 54 percent in November 2016. The repeal measure was certified for the ballot in July after proponents submitted 112,000 verified signatures, exceeding the 74,574 threshold required under state constitutional procedures. If it passes, Massachusetts would become the first state to reverse adult-use legalization through a statewide referendum.
Stakes for 400 Licensed Operators
Massachusetts currently licenses 403 adult-use cannabis retailers, cultivators, and product manufacturers, according to August data from the state Cannabis Control Commission. Those businesses generated $1.8 billion in gross sales in 2025, producing $276 million in excise and sales tax revenue. A successful repeal wouldn't automatically shutter existing operations—state statute would require the legislature to enact implementing language. But operators face immediate credit and lease-renewal uncertainty.
The economic disruption would extend far beyond dispensary closures, affecting ancillary vendors, real estate holders, and municipal budgets that've integrated cannabis tax receipts into baseline revenue projections.
Repeal Campaign Frames Issue as Public Health Concern
The Coalition for Safe Communities, the political action committee backing Question 4, argues that youth cannabis use has risen 17 percent since 2018. That figure draws from the state Department of Public Health's Youth Risk Behavior Survey, though public health researchers have noted the survey's methodology changed in 2021, complicating year-over-year comparisons. The coalition has raised $4.2 million through August. Contributors include hospital systems and substance-use treatment providers.
Industry and Advocacy Groups Mount Opposition
The Campaign to Protect Massachusetts Cannabis, the opposition PAC, has raised $6.7 million, primarily from MSOs including Curaleaf, Trulieve, and Ascend Wellness. Advocacy organizations including the Massachusetts Cannabis Association for Delivery and the Minority Cannabis Business Association have endorsed the opposition campaign. Polling conducted in late August by Suffolk University showed 48 percent of likely voters opposing repeal, 39 percent supporting it, and 13 percent undecided.
Legislative Response Uncertain if Measure Passes
Massachusetts law doesn't provide an automatic sunset mechanism for Question 4; the legislature would need to pass implementing language within 180 days of certification. That timeline would compress decision-making into the first quarter of 2027, overlapping with the legislature's budget cycle. House Speaker Ronald Mariano hasn't taken a public position on Question 4. Senate President Karen Spilka declined to comment when asked by reporters in August.
What to Watch Through November
The next major inflection point is the October 15 campaign finance filing deadline, which will reveal whether late donations shift the spending balance. Voter turnout models will also matter: Massachusetts midterm electorates skew older and whiter than presidential-year turnout, demographics that correlate with higher repeal support in Suffolk's crosstabs. For full background on this story, see the CannIntel topic hub on the Massachusetts cannabis repeal vote.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws

DEA Accepts New Report in Rescheduling Hearing; Foes Seek Discovery
DEA does not object to a new report entering the marijuana rescheduling record, while opponents ask for added testimony and document discovery.

Puerto Rico Rolls Back Medical Cannabis Workplace Protections
High Times Magazine reports Puerto Rico has narrowed employment protections for medical cannabis patients, raising questions about which workers lose coverage and which keep it.

L.A. Cannabis Industry Rallies Behind Nithya Raman, Substack Reports
A High Adam post says Los Angeles operators are energizing around Councilmember Nithya Raman, but the platform details behind the 'actual plan' remain unverified.
More from the newsroom

Organigram enters fight for Aurora as Curaleaf bid clock runs
British American Tobacco's stake in Organigram could put the tobacco giant at the center of the Aurora contest before Curaleaf's offer expires Dec. 4.

Tilray Medical Wins Approval for In-House EU-GMP Cannabis Testing
Tilray Medical can now run EU-GMP quality testing in-house, a move that could shift lab costs and batch-release timing, though key details remain undisclosed.

County Commissioners Vote for Cannabis Moratorium, Herald Reports
A county board voted to pause new cannabis operations, the Austin Daily Herald reported, adding to Minnesota's patchwork of local rules under the 2023 adult-use law.